Preclinical Testing News and Research

RSS

New method based on human blood simplifies mRNA drug development

mRNA-based drugs are emerging as the drug of the future for a wide range of diseases, but they are difficult and time-consuming to develop.

1 Sep 2026

Multiple sclerosis treatment approach developed at Mainz University moves toward clinical application

A therapeutic approach pioneered in Mainz for the treatment of multiple sclerosis (MS) is taking an important step toward clinical application.

1 Sep 2026

Experimental gene therapy reverses fragile X symptoms in mice

A gene therapy designed to replace the missing protein that causes fragile X syndrome restored several disease-relevant traits in a mouse model, according to a new study published in Gene Therapy.

14 Jul 2026

AI-driven approach identifies promising new target for CAR T cell therapy

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists' expertise to find viable target antigens for CAR T cell therapy.

25 Jun 2026

Study identifies key fibrotic cells driving hypertrophic scars

Hypertrophic scars (HS) are abnormal outcomes of wound healing, marked by excessive extracellular matrix (ECM) deposition and impaired scar remodeling.

25 Jun 2026

Injectable wireless device offers new approach to control nerve activity

Researchers from NYU Abu Dhabi, in collaboration with Cleveland Clinic Abu Dhabi, have developed a tiny, injectable medical device that introduces a new approach to treating chronic pain and movement disorders by controlling nerve activity without the need for surgery, batteries, or wires, offering a simpler and less invasive way to treat neurological conditions.

12 Jun 2026

Advancing Human Muscle Models for Drug Development and Preclinical Testing

Transforming drug development, Myomaker Bio's lab-grown muscle platforms offer human-relevant models for effective preclinical testing and risk reduction.

From Myomaker Bio 2 Jun 2026

The power of organoids in speeding up lifesaving drug development

Organoids are miniature tissue or organ models formed by stem cells (including pluripotent stem cells, tissue-specific adult stem cells, etc.) or progenitor cells in an in vitro three-dimensional culture system, which possess structural features and partial functions analogous to their corresponding in vivo organs. In 2009, the Hans Clevers laboratory developed the first intestinal organoid, marking the inception of organoid-based disease modeling.

8 May 2026

Novo Nordisk principal scientist highlights the urgency of advancing human-relevant 3D tissue models ahead of the 11th 3D Tissue Models Summit

As regulatory momentum accelerates globally to reduce reliance on animal testing, leading experts in microphysiological systems (MPS), complex in vitro models (CIVMs), organoids, and organ‑on‑chip technologies are preparing to gather at the 11th 3D Tissue Models Summit, taking place April 28–30, 2026 in Boston.

From Hanson Wade Group - 11th 3D Tissue Models Summit 2026 27 Mar 2026

Immune dysfunction persists after combined TB and HIV therapy

The immune system remains seriously out-of-whack – in an inflammatory state of overactivation and impaired functionality – following the international gold standard for treating people with latent tuberculosis (TB) and HIV, a team at Texas Biomedical Research Institute reports in Nature Communications.

14 Jan 2026

Study validates OVCAR3 as a model for high-grade serous ovarian cancer

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA sequencing-based profiling of TP53."

23 Dec 2025

Human heart organoids enable new therapies for atrial fibrillation

Though an estimated 60 million people around the world have atrial fibrillation, or A-fib, a type of irregular and often fast heartbeat, it's been at least 30 years since any new treatments have been developed.

12 Dec 2025

Organ-on-a-chip system reveals how aging weakens vaccine-driven anti-cancer immunity

Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates age-dependent immune responses, offering a more accurate testing bed for evaluating cancer vaccine performance in older adults, the population most affected by cancer and often overlooked in traditional preclinical testing.

4 Dec 2025

Cellarity's AI model predicts drug-induced liver injury

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the publication of a seminal manuscript in Nature Communications, which describes a novel framework for the prediction and characterization of drug-induced liver injury (DILI), along with open-source posting of the model and validation data.

13 Nov 2025